Hong Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hong Cao has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dmytro Kornyeyev
Gilead Sciences, Inc., Foster City, California, USA
1 shared publication - Eugene W. Krueger
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication - Huiling Yang
Gilead Sciences, Inc., Foster City, California, USA
1 shared publication - Jane Tam
Gilead Sciences, Inc., Foster City, California, USA
1 shared publication - Jia Jun Chia
Gilead Sciences, Inc., Foster City, California, USA
1 shared publication - Jing Chen
Center for Basic Research in Digestive Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
1 shared publication
Latest Publications
- Open Access
- 22 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Secretion of the HBV small surface antigen is driven by an ER autophagic pathway
Chronic hepatitis B (CHB), a major global public health burden, is characterized by the presence of high circulating levels of non-infectious subviral particles (SVPs). These SVPs are mainly composed of small hepatitis B surface antigen (SHBs) and are associated with a dysfunctional HBV-specific immune response. Previous studies exploring the cellular mechanisms and molecular pathways by which SVPs are secreted from hepatocytes have utilized either non-hepatic cells or whole-genome HBV-integrated hepatoma cell lines in which SHBs can also be secreted as a component of the virion envelope. In this study, we provide a detailed examination of SHBs trafficking using biochemical approaches coupled with high-resolution confocal microscopy and live-cell imaging via a novel fluorophore-tagged SHBs probe in both HepG2 and primary human hepatocytes stably expressing SHBs. Our results provide evidence that SHBs utilize a modified ER-Golgi secretory pathway with transit from the ER to the multivesicular body and lysosomal/late endosomal compartments. Importantly, we identified the autophagy adapters ATG5 and LC3B, and the ER-phagy protein atlastin 3 (ATL3), central to mediating SHBs secretion. These findings suggest that SHBs is trafficked through a non-canonical path for secretion and provides new potential therapeutic targets for the treatment of CHB.
- 22 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Open AccessSecretion of the HBV small surface antigen is driven by an ER autophagic pathway
Chronic hepatitis B (CHB), a major global public health burden, is characterized by the presence of high circulating levels of non-infectious subviral particles (SVPs). These SVPs are mainly composed of small hepatitis B surface antigen (SHBs) and are associated with a dysfunctional HBV-specific immune response. Previous studies exploring the cellular mechanisms and molecular pathways by which SVPs are secreted from hepatocytes have utilized either non-hepatic cells or whole-genome HBV-integrated hepatoma cell lines in which SHBs can also be secreted as a component of the virion envelope. In this study, we provide a detailed examination of SHBs trafficking using biochemical approaches coupled with high-resolution confocal microscopy and live-cell imaging via a novel fluorophore-tagged SHBs probe in both HepG2 and primary human hepatocytes stably expressing SHBs. Our results provide evidence that SHBs utilize a modified ER-Golgi secretory pathway with transit from the ER to the multivesicular body and lysosomal/late endosomal compartments. Importantly, we identified the autophagy adapters ATG5 and LC3B, and the ER-phagy protein atlastin 3 (ATL3), central to mediating SHBs secretion. These findings suggest that SHBs is trafficked through a non-canonical path for secretion and provides new potential therapeutic targets for the treatment of CHB.